Related Experiment Video

Updated: Jul 3, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

PPAR delta: a dagger in the heart of the metabolic syndrome

Grant D Barish1, Vihang A Narkar, Ronald M Evans

  • 1Howard Hughes Medical Institute, Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, California 92037-1099, USA.

The Journal of Clinical Investigation
|March 3, 2006
PubMed

Insights

Peroxisome proliferator-activated receptor delta (PPARdelta) shows promise for treating metabolic syndrome. This nuclear receptor may help manage weight gain, improve insulin sensitivity, and reduce inflammation.

Area of Science:

  • Metabolic disease research
  • Nuclear receptor pharmacology
  • Obesity and metabolic syndrome

Background:

  • Obesity is a global health concern linked to metabolic syndrome, characterized by insulin resistance, glucose intolerance, hypertension, and dyslipidemia.
  • Nuclear receptors PPARalpha and PPARgamma are established therapeutic targets for hypertriglyceridemia and insulin resistance, respectively.
  • PPARdelta, a less-described isotype, is emerging as a potential therapeutic target for metabolic diseases.

Purpose of the Study:

  • To explore the therapeutic potential of PPARdelta in treating metabolic syndrome.
  • To investigate PPARdelta's dual benefits for hypertriglyceridemia and insulin resistance.
  • To highlight PPARdelta's multifaceted role in metabolic disease management.

Main Methods:

  • Review of existing research on PPARdelta.
  • Analysis of PPARdelta's molecular mechanisms in adipose tissue, muscle, and macrophages.
  • Evaluation of PPARdelta's potential clinical applications.

Main Results:

  • PPARdelta enhances fatty acid catabolism and energy uncoupling in key metabolic tissues.
  • PPARdelta demonstrates anti-inflammatory effects by suppressing macrophage activity.
  • PPARdelta activation shows potential for weight management and improved physical endurance.

Conclusions:

  • PPARdelta represents a promising therapeutic target for metabolic syndrome.
  • Targeting PPARdelta may offer a multifaceted approach to managing obesity, insulin resistance, and related conditions.
  • Further research into PPARdelta modulation could lead to novel treatments for metabolic diseases.

More Related Videos

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro09:41

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Published on: March 17, 2023

Related Concept Videos

cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.